Related Experiment Videos
Haloperidol in schizophrenic children: early findings from a study in progress
E K Spencer1, V Kafantaris, M V Padron-Gayol
1Department of Psychiatry, New York University School of Medicine, NY.
Psychopharmacology Bulletin
|January 1, 1992
Summary
Haloperidol effectively reduced symptoms in hospitalized children with schizophrenia. This antipsychotic medication showed superiority over placebo in preliminary findings for pediatric psychiatric care.
Area of Science:
- Child and Adolescent Psychiatry
- Psychopharmacology
- Clinical Psychology
Background:
- Schizophrenia in children presents unique diagnostic and treatment challenges.
- Hospitalized pediatric populations require careful consideration for antipsychotic interventions.
- Existing research on haloperidol in pediatric schizophrenia is limited.
Purpose of the Study:
- To evaluate the safety and efficacy of haloperidol in hospitalized schizophrenic children.
- To determine optimal dosage ranges for haloperidol treatment in this population.
- To compare haloperidol's effects against a placebo in a pediatric cohort.
Main Methods:
- Double-blind, placebo-controlled, crossover study design.
- Inclusion of children diagnosed with schizophrenia based on DSM-III-R criteria.
- Individualized haloperidol dosage ranging from 0.5 to 10.0 mg/day over 8 weeks of treatment.
Main Results:
- Preliminary findings indicate haloperidol is superior to placebo in reducing target symptoms.
- Optimal haloperidol dosage identified between 0.5 to 3.5 mg/day (0.02-0.12 mg/kg/day).
- 12 out of 20 anticipated subjects completed the 10-week study.
Conclusions:
- Haloperidol demonstrates efficacy in treating hospitalized schizophrenic children.
- Further research is warranted to confirm these preliminary findings.
- The study provides evidence for targeted haloperidol dosing in pediatric psychiatric settings.